---

title: "Autonomic symptom burden, comorbidities and quality of life in women with Hypermobility Spectrum Disorders and hypermobile Ehlers-Danlos syndrome."
tags:
- ➕ 2025-12-25
created: '2025-10-14'
published: '2025-10-14'

---


<details>
<summary>Hutchinson et al. (2024)</summary>

- **Authors:** Meagan Hutchinson, Emily Liang, Emily Fuster, Svetlana Blitshteyn.
- **Institutes:** Dysautonomia Clinic, Buffalo, NY; University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY.
- **Publisher:** Autonomic Neuroscience: Basic and Clinical
- **Link:** [PubMed](https://pubmed.ncbi.nlm.nih.gov/41118678)

</details>


## Summary

This study confirms that hypermobility disorders are far more than just "loose joints"; they are systemic conditions that frequently overlap with ME/CFS and dysautonomia. For patients, this research validates the severity of their lived experience, showing that the physical and autonomic burden of HSD/h-EDS can be more debilitating than that of many other high-profile chronic illnesses. By documenting the high prevalence of the HSD/POTS/MCAS triad, the study underscores the importance of screening for these related conditions during the diagnostic process. This objective data provides a strong argument for more comprehensive medical support and a shift in how these disorders are prioritized within the healthcare system.

## What was researched?

This study investigated the severity of autonomic nervous system symptoms, the frequency of co-occurring medical conditions (such as POTS, MCAS, and ME/CFS), and the overall quality of life in women diagnosed with Hypermobility Spectrum Disorders (HSD) or hypermobile Ehlers-Danlos syndrome (h-EDS). The goal was to quantify how these connective tissue disorders affect daily functioning and physical health.

## Why was it researched?

While joint hypermobility is the hallmark of HSD and h-EDS, many patients suffer from widespread systemic issues including chronic pain, fatigue, and "dysautonomia" (malfunction of the autonomic nervous system). There has been limited data comparing the severity of these symptoms to other chronic illnesses, and researchers wanted to better understand the prevalence of the "clinical triad"—the simultaneous occurrence of hypermobility, POTS, and MCAS.

## How was it researched?

This was a cross-sectional study involving a cohort of 84 women with physician-diagnosed HSD or h-EDS who completed standardized, anonymous health questionnaires. The researchers used the COMPASS-31 scale to measure autonomic symptom severity, the SF-36 to assess quality of life (QoL), and the Beck Depression Inventory (BDI-II) to evaluate psychological impact. The data were then compared to existing benchmarks for other chronic conditions like multiple sclerosis, rheumatoid arthritis, and diabetic neuropathy.

## What has been found?

The study revealed an extremely high burden of illness: 98.8% of participants suffered from chronic pain, 58.3% had Postural Orthostatic Tachycardia Syndrome (POTS), 32.1% had Mast Cell Activation Syndrome (MCAS), and 26.2% met the criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Notably, 25% of the women lived with the full "clinical triad" of HSD/h-EDS, POTS, and MCAS. Patients reported severe autonomic dysfunction and a quality of life that was significantly lower than that of patients with other major chronic diseases, including multiple sclerosis and lupus.

## Discussion

The authors highlight that the autonomic burden in HSD and h-EDS is often underestimated and is actually more severe than in many well-recognized neurological and autoimmune conditions. A primary limitation noted is the relatively small, female-only cohort, which may not represent all individuals with these conditions. However, the study's strength lies in its use of validated tools to provide a clear comparison of the multisystemic nature of hypermobility disorders.

## Conclusion & Future Work

The researchers conclude that women with HSD and h-EDS face a profound multisystemic health challenge characterized by severe dysautonomia and poor quality of life. They emphasize the need for a multidisciplinary approach to treatment that addresses the various comorbidities. Future research is needed to investigate the underlying mechanisms of this disease cluster and to develop more effective, targeted therapies for this patient population.
